Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients

Cristina Baleriola; William Rawlinson; Gregory J Dore; Sandra Chaverot; Sacha Stelzer-Braid; Motoko Yoshihara; Darrell Crawford; William Sievert; Geoffrey McCaughan; Martin Weltman; Wendy Cheng; Bishoy Rizkalla; Dwight Dubois; James Thommes; Stuart Roberts

doi:10.3851/IMP1731

Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients

Cristina Baleriola
, William Rawlinson
, Gregory J Dore
, Sandra Chaverot
, Sacha Stelzer-Braid
, Motoko Yoshihara
, Darrell Crawford
, William Sievert
, Geoffrey McCaughan
, Martin Weltman
, Wendy Cheng
, Bishoy Rizkalla
, Dwight Dubois
, James Thommes
, Stuart Roberts

Medicine Monash Health

Research output: Contribution to journal › Article › Research › peer-review

1 Citation (Scopus)

Abstract

We examined the detection of low-level viraemia at week 24 as a predictor of sustained virological response (SVR) and viral relapse/breakthrough, and the agreement between the Roche Cobas TaqMana?? HCV RNA assay (TaqMan) and Roche Cobas(A?) Amplicor HCV qualitative assay (Amplicor; both Roche Molecular Diagnostics, Pleasanton, CA, USA) for detection of low-level viraemia.

Original language	English
Pages (from-to)	173 - 180
Number of pages	8
Journal	Antiviral Therapy
Volume	16
Issue number	2
DOIs	https://doi.org/10.3851/IMP1731
Publication status	Published - 2011

Access to Document

10.3851/IMP1731

Cite this

Baleriola, C., Rawlinson, W., Dore, G. J., Chaverot, S., Stelzer-Braid, S., Yoshihara, M., Crawford, D., Sievert, W., McCaughan, G., Weltman, M., Cheng, W., Rizkalla, B., Dubois, D., Thommes, J., & Roberts, S. (2011). Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients. Antiviral Therapy, 16(2), 173 - 180. https://doi.org/10.3851/IMP1731

@article{391cd974597f4225a9df8412d389810e,

title = "Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients",

abstract = "We examined the detection of low-level viraemia at week 24 as a predictor of sustained virological response (SVR) and viral relapse/breakthrough, and the agreement between the Roche Cobas TaqMana?? HCV RNA assay (TaqMan) and Roche Cobas(A?) Amplicor HCV qualitative assay (Amplicor; both Roche Molecular Diagnostics, Pleasanton, CA, USA) for detection of low-level viraemia.",

author = "Cristina Baleriola and William Rawlinson and Dore, \{Gregory J\} and Sandra Chaverot and Sacha Stelzer-Braid and Motoko Yoshihara and Darrell Crawford and William Sievert and Geoffrey McCaughan and Martin Weltman and Wendy Cheng and Bishoy Rizkalla and Dwight Dubois and James Thommes and Stuart Roberts",

year = "2011",

doi = "10.3851/IMP1731",

language = "English",

volume = "16",

pages = "173 -- 180",

journal = "Antiviral Therapy",

issn = "1359-6535",

publisher = "SAGE Publications Ltd",

number = "2",

}

Baleriola, C, Rawlinson, W, Dore, GJ, Chaverot, S, Stelzer-Braid, S, Yoshihara, M, Crawford, D, Sievert, W, McCaughan, G, Weltman, M, Cheng, W, Rizkalla, B, Dubois, D, Thommes, J & Roberts, S 2011, 'Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients', Antiviral Therapy, vol. 16, no. 2, pp. 173 - 180. https://doi.org/10.3851/IMP1731

TY - JOUR

T1 - Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients

AU - Baleriola, Cristina

AU - Rawlinson, William

AU - Dore, Gregory J

AU - Chaverot, Sandra

AU - Stelzer-Braid, Sacha

AU - Yoshihara, Motoko

AU - Crawford, Darrell

AU - Sievert, William

AU - McCaughan, Geoffrey

AU - Weltman, Martin

AU - Cheng, Wendy

AU - Rizkalla, Bishoy

AU - Dubois, Dwight

AU - Thommes, James

AU - Roberts, Stuart

PY - 2011

Y1 - 2011

N2 - We examined the detection of low-level viraemia at week 24 as a predictor of sustained virological response (SVR) and viral relapse/breakthrough, and the agreement between the Roche Cobas TaqMana?? HCV RNA assay (TaqMan) and Roche Cobas(A?) Amplicor HCV qualitative assay (Amplicor; both Roche Molecular Diagnostics, Pleasanton, CA, USA) for detection of low-level viraemia.

AB - We examined the detection of low-level viraemia at week 24 as a predictor of sustained virological response (SVR) and viral relapse/breakthrough, and the agreement between the Roche Cobas TaqMana?? HCV RNA assay (TaqMan) and Roche Cobas(A?) Amplicor HCV qualitative assay (Amplicor; both Roche Molecular Diagnostics, Pleasanton, CA, USA) for detection of low-level viraemia.

UR - http://www.intmedpress.com/journals/avt/abstract.cfm?id=1731&pid=48

U2 - 10.3851/IMP1731

DO - 10.3851/IMP1731

M3 - Article

SN - 1359-6535

VL - 16

SP - 173

EP - 180

JO - Antiviral Therapy

JF - Antiviral Therapy

IS - 2

ER -

Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients

Abstract

Access to Document

Other files and links

Cite this